

Global Gene Therapy Market - Industry Trends and Forecast to 2030

Market Report | 2023-03-01 | 216 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$4800.00
- Corporate Users License \$7000.00

Report description:

Global gene therapy market is projected to register a CAGR of 18.3% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Global Gene Therapy Market, By Vector Type (Viral Vector and Non-viral Vector), Method (Ex-vivo and In-vivo), Application (Oncological Disorders, Cardiovascular Diseases, Infectious Diseases, Rare Diseases, Neurological Disorders, and Other Diseases), End User (Cancer Institutes, Hospitals, Research institutes, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey, Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, South Africa, Rest of Middle East and Africa, Brazil, and Rest of South America) Industry Trends and Forecast to 2030

Some of the major factors contributing to the growth of the gene therapy market are:

- Rising demand of personalized medicine
- Rising prevalence of genetic disorders
- Novel approaches of gene therapy

Market Players:

The key market players for global gene therapy market are listed below:

- AGC Biologics
- Amgen, Inc.
- AnGes, Inc
- Biogen
- bluebird bio, Inc.
- Bristol Myers Squibb Company
- CHIESI Farmaceutici S.p.A.
- Dendreon Pharmaceuticals LLC
- Enzyvant Therapeutics GmbH

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Ferring B.V.
- Janssen Pharmaceuticals, Inc.
- Kite Pharma (a subsidiary of Gilead Sciences, Inc.)
- Mallinckrodt.
- Novartis AG
- Orchard Therapeutics plc.
- Oxford Biomedica
- Shanghai Sunway Biotech Co., Ltd.
- SIBONO
- Spark Therapeutics, Inc.
- uniQure NV.

Table of Contents:

TABLE OF CONTENTS

1 INTRODUCTION	21
1.1 OBJECTIVES OF THE STUDY	21
1.2 MARKET DEFINITION	21
1.3 OVERVIEW OF THE GLOBAL GENE THERAPY MARKET	21
1.4 CURRENCY AND PRICING	23
1.5 LIMITATIONS	23
1.6 MARKETS COVERED	23
2 MARKET SEGMENTATION	25
2.1 MARKETS COVERED	25
2.2 GEOGRAPHICAL SCOPE	26
2.3 YEARS CONSIDERED FOR THE STUDY	27
2.4 DBMR TRIPOD DATA VALIDATION MODEL	28
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	31
2.6 MULTIVARIATE MODELLING	32
2.7 MARKET END USER COVERAGE GRID	32
2.8 PRODUCT LIFELINE CURVE	33
2.9 DBMR MARKET POSITION GRID	34
2.10 VENDOR SHARE ANALYSIS	35
2.11 SECONDARY SOURCES	36
2.12 ASSUMPTIONS	36
3 EXECUTIVE SUMMARY	37
4 PREMIUM INSIGHTS	40
4.1 PESTEL ANALYSIS	43
4.2 PORTER FIVE ANALYSIS	44
5 UPDATE ON GERMLINE GENE THERAPY	45
5.1 GERMLINE GENE THERAPY	45
6 GLOBAL GENE THERAPY MARKET, MO	46
6.1 DRIVERS	48
6.1.1 NOVEL APPROACHES TO GENE THERAPY	48

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.1.2 INCREASING PREVALENCE OF GENETIC DISORDERS 48
- 6.1.3 THE GROWING INVESTMENT BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES 49
- 6.1.4 GROWING DEMAND FOR PERSONALIZED MEDICINE 50
- 6.2 RESTRAINTS 50
 - 6.2.1 HIGH COST OF GENE THERAPY 50
 - 6.2.2 ETHICAL AND SAFETY CONCERNS 51
 - 6.2.3 COMPLEXITY OF GENE THERAPY 51
- 6.3 OPPORTUNITIES 52
 - 6.3.1 RISE IN STRATEGIC ACQUISITION AND PARTNERSHIP AMONG ORGANIZATIONS 52
 - 6.3.2 RISING APPROVAL FOR GENE THERAPY PRODUCTS 52
- 6.4 CHALLENGES 53
 - 6.4.1 STRINGENT REGULATIONS FOR GENE THERAPY PRODUCTS 53
 - 6.4.2 LONG-TERM SAFETY AND EFFICACY 53
- 7 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE 54
 - 7.1 OVERVIEW 55
 - 7.2 VIRAL VECTOR 58
 - 7.2.1 ADENOVIRUS 59
 - 7.2.2 RETROVIRUS 59
 - 7.2.3 LENTIVIRUS 59
 - 7.2.4 ADENO-ASSOCIATED VIRUS 59
 - 7.2.5 VACCINIA VIRUS 59
 - 7.2.6 HERPES SIMPLEX VIRUS 59
 - 7.2.7 OTHERS 59
 - 7.3 NON-VIRAL VECTOR 59
 - 7.3.1 LIPOFECTION 60
 - 7.3.2 INJECTION OF NAKED DNA 60
- 8 GLOBAL GENE THERAPY MARKET, BY METHOD 61
 - 8.1 OVERVIEW 62
 - 8.2 EX-VIVO 65
 - 8.3 IN-VIVO 65
- 9 GLOBAL GENE THERAPY MARKET, BY APPLICATION 67
 - 9.1 OVERVIEW 68
 - 9.2 ONCOLOGICAL DISORDERS 71
 - 9.3 CARDIOVASCULAR DISEASES 71
 - 9.4 INFECTIOUS DISEASES 72
 - 9.5 RARE DISEASES 73
 - 9.6 NUEROLOGICAL DISORDERS 74
 - 9.7 OTHER DISEASES 75
- 10 GLOBAL GENE THERAPY MARKET, BY END USER 76
 - 10.1 OVERVIEW 77
 - 10.2 CANCER INSTITUTES 80
 - 10.3 HOSPITALS 80
 - 10.4 RESEARCH INSTITUTES 81
 - 10.5 OTHERS 82
- 11 GLOBAL GENE THERAPY MARKET, BY REGION 83
 - 11.1 OVERVIEW 84
 - 11.2 NORTH AMERICA 89

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.2.1 U.S. 95
- 11.2.2 CANADA 97
- 11.2.3 MEXICO 99
- 11.3 EUROPE 101
 - 11.3.1 GERMANY 107
 - 11.3.2 FRANCE 109
 - 11.3.3 U.K. 111
 - 11.3.4 ITALY 113
 - 11.3.5 SPAIN 115
 - 11.3.6 RUSSIA 117
 - 11.3.7 TURKEY 119
 - 11.3.8 NETHERLANDS 121
 - 11.3.9 BELGIUM 123
 - 11.3.10 SWITZERLAND 125
 - 11.3.11 REST OF EUROPE 127
- 11.4 ASIA-PACIFIC 128
 - 11.4.1 CHINA 134
 - 11.4.2 JAPAN 136
 - 11.4.3 SOUTH KOREA 138
 - 11.4.4 INDIA 140
 - 11.4.5 AUSTRALIA 142
 - 11.4.6 SINGAPORE 144
 - 11.4.7 THAILAND 146
 - 11.4.8 MALAYSIA 148
 - 11.4.9 INDONESIA 150
 - 11.4.10 PHILIPPINES 152
 - 11.4.11 REST OF ASIA-PACIFIC 154
- 11.5 SOUTH AMERICA 155
 - 11.5.1 BRAZIL 161
 - 11.5.2 REST OF SOUTH AMERICA 163
- 11.6 MIDDLE EAST AND AFRICA 164
 - 11.6.1 SOUTH AFRICA 170
 - 11.6.2 REST OF MIDDLE EAST AND AFRICA 172
- 12 GLOBAL GENE THERAPY MARKET, COMPANY LANDSCAPE 173
 - 12.1 COMPANY SHARE ANALYSIS: GLOBAL 173
 - 12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 174
 - 12.3 COMPANY SHARE ANALYSIS: EUROPE 175
 - 12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 176
- 13 COMPANY PROFILES 177
 - 13.1 BIOGEN 177
 - 13.1.1 COMPANY SNAPSHOT 177
 - 13.1.2 REVENUE ANALYSIS 177
 - 13.1.3 COMPANY SHARE ANALYSIS 178
 - 13.1.4 SWOT ANALYSIS 178
 - 13.1.5 PRODUCT PORTFOLIO 179
 - 13.1.6 RECENT DEVELOPMENT 179
 - 13.2 KITE PHARMA 180

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.2.1	COMPANY SNAPSHOT	180
13.2.2	REVENUE ANALYSIS	180
13.2.3	COMPANY SHARE ANALYSIS	181
13.2.4	SWOT ANALYSIS	181
13.2.5	PRODUCT PORTFOLIO	182
13.2.6	RECENT DEVELOPMENT	182
13.3	NOVARTIS AG	183
13.3.1	COMPANY SNAPSHOT	183
13.3.2	REVENUE ANALYSIS	183
13.3.3	COMPANY SHARE ANALYSIS	184
13.3.4	SWOT ANALYSIS	184
13.3.5	PRODUCT PORTFOLIO	185
13.3.6	RECENT DEVELOPMENTS	185
13.4	BRISTOL-MYERS SQUIBB COMPANY.	186
13.4.1	COMPANY SNAPSHOT	186
13.4.2	REVENUE ANALYSIS	186
13.4.3	COMPANY SHARE ANALYSIS	187
13.4.4	SWOT ANALYSIS	187
13.4.5	PRODUCT PORTFOLIO	188
13.4.6	RECENT DEVELOPMENT	188
13.5	OXFORD BIOMEDICA	189
13.5.1	COMPANY SNAPSHOT	189
13.5.2	REVENUE ANALYSIS	189
13.5.3	COMPANY SHARE ANALYSIS	190
13.5.4	SWOT ANALYSIS	190
13.5.5	PRODUCT PORTFOLIO	191
13.5.6	RECENT DEVELOPMENTS	191
13.6	AGC BIOLOGICS	192
13.6.1	COMPANY SNAPSHOT	192
13.6.2	PRODUCT PORTFOLIO	192
13.6.3	RECENT DEVELOPMENT	192
13.7	ANGES, INC	193
13.7.1	COMPANY SNAPSHOT	193
13.7.2	REVENUE ANALYSIS	193
13.7.3	PRODUCT PORTFOLIO	194
13.7.4	RECENT DEVELOPMENT	194
13.8	AMGEN INC.	195
13.8.1	COMPANY SNAPSHOT	195
13.8.2	REVENUE ANALYSIS	195
13.8.3	PRODUCT PORTFOLIO	196
13.8.4	RECENT DEVELOPMENT	196
13.9	BLUEBIRD BIO, INC.	197
13.9.1	COMPANY SNAPSHOT	197
13.9.2	PRODUCT PORTFOLIO	197
13.9.3	RECENT DEVELOPMENT	197
13.10	CHIESI FARMACEUTICI S.P.A	198
13.10.1	COMPANY SNAPSHOT	198

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.10.2 REVENUE ANALYSIS	198
13.10.3 PRODUCT PORTFOLIO	199
13.10.4 RECENT DEVELOPMENT	199
13.11 DENDREON PHARMACEUTICALS LLC	200
13.11.1 COMPANY SNAPSHOT	200
13.11.2 PRODUCT PORTFOLIO	200
13.11.3 RECENT DEVELOPMENT	200
13.12 ENZYVANT THERAPEUTICS GMBH	201
13.12.1 COMPANY SNAPSHOT	201
13.12.2 PRODUCT PORTFOLIO	201
13.12.3 RECENT DEVELOPMENT	201
13.13 FERRING B.V.	202
13.13.1 COMPANY SNAPSHOT	202
13.13.2 PRODUCT PORTFOLIO	202
13.13.3 RECENT DEVELOPMENT	202
13.14 JANSSEN PHARMACEUTICALS, INC.	203
13.14.1 COMPANY SNAPSHOT	203
13.14.2 PRODUCT PORTFOLIO	203
13.14.3 RECENT DEVELOPMENT	203
13.15 MALLINCKRODT.	204
13.15.1 COMPANY SNAPSHOT	204
13.15.2 REVENUE ANALYSIS	204
13.15.3 PRODUCT PORTFOLIO	205
13.15.4 RECENT DEVELOPMENT	205
13.16 ORCHARD THERAPEUTICS PLC.	206
13.16.1 COMPANY SNAPSHOT	206
13.16.2 REVENUE ANALYSIS	206
13.16.3 PRODUCT PORTFOLIO	207
13.16.4 RECENT DEVELOPMENT	207
13.17 SHANGHAI SUNWAY BIOTECH CO., LTD.	208
13.17.1 COMPANY SNAPSHOT	208
13.17.2 PRODUCT PORTFOLIO	208
13.17.3 RECENT DEVELOPMENT	208
13.18 SIBONO	209
13.18.1 COMPANY SNAPSHOT	209
13.18.2 PRODUCT PORTFOLIO	209
13.18.3 RECENT DEVELOPMENT	209
13.19 SPARK THERAPEUTICS, INC.	210
13.19.1 COMPANY SNAPSHOT	210
13.19.2 PRODUCT PORTFOLIO	210
13.19.3 RECENT DEVELOPMENT	210
13.20 UNIQUIRE NV.	211
13.20.1 COMPANY SNAPSHOT	211
13.20.2 REVENUE ANALYSIS	211
13.20.3 PRODUCT PORTFOLIO	212
13.20.4 RECENT DEVELOPMENT	212
14 QUESTIONNAIRE	213

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Gene Therapy Market - Industry Trends and Forecast to 2030

Market Report | 2023-03-01 | 216 pages | Data Bridge Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4800.00
	Corporate Users License	\$7000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-02"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com